Arbutus Biopharma (ABUS) Other financing activities (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Other financing activities for 14 consecutive years, with $11.5 million the latest figure, recorded in Q1 2026.

• Quarterly Other financing activities rose 334.64% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (up 87.83% YoY) and the FY2025 annual result came in at $5.5 million, down 25.91% from the prior year.
• Other financing activities climbed to $11.5 million in Q1 2026 per ABUS's latest filing, from $1.6 million in the prior quarter.
• Over the last five years, Other financing activities for ABUS reached as high as $11.5 million in Q1 2026 and fell as low as -$46000.0 in Q4 2023.
• A 5-year average of $1.8 million and a median of $1.1 million in 2024 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities slumped 91.96% — and 2024, when it jumped 3191.3%.
• Year by year, Other financing activities stood at $159000.0 in 2022, then tumbled by 128.93% to -$46000.0 in 2023, then jumped by 3191.3% to $1.4 million in 2024, then increased by 15.33% to $1.6 million in 2025, then surged by 603.11% to $11.5 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $11.5 million, $1.6 million, and $794000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.